Search

Zentalis Pharmaceuticals Inc

Fermé

3.03 -1.62

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.99

Max

3.1

Chiffres clés

By Trading Economics

Revenu

-42M

-78M

BPA

-0.59

Employés

106

EBITDA

-42M

-77M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+182.96% upside

Dividendes

By Acuity

Prochains Résultats

6 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

335K

331M

Ouverture précédente

4.65

Clôture précédente

3.03

Zentalis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 sept. 2026, 23:56 UTC

Revvity Inc is trading modestly higher in after-market hours, positioned above its 20-day moving average and near the upper end of its one-month range.

21 sept. 2026, 23:56 UTC

Correlated Moves

Eversource Energy is advancing in after-market hours, influenced by OGE Energy's gains earlier in the session, though it remains below its 20-day moving average.

21 sept. 2026, 23:56 UTC

Owens Corning is trading modestly higher in after-market hours, recovering from a recent trend of six consecutive sessions ending lower.

21 sept. 2026, 23:56 UTC

Ameriprise Financial Inc is trading slightly higher in after-market hours, recovering from an earlier dip but remains below its 20-day moving average.

21 sept. 2026, 23:56 UTC

Pool Corp is trading modestly higher in after-market hours following a decline in the Chicago Fed National Activity Index for August, reflecting slower economic growth.

21 sept. 2026, 23:55 UTC

Chimera Investment Corp is trading roughly flat in after-market hours, about 2.48% below its 20-day moving average.

21 sept. 2026, 23:55 UTC

Lamb Weston Holdings Inc is trading modestly lower in after-market hours, continuing the earlier session's weakness and remaining below its 20-day moving average.

21 sept. 2026, 23:55 UTC

Ziff Davis Inc declined during after-market hours on Monday, influenced by broader economic slowdown signals, despite remaining above its 20-day moving average.

21 sept. 2026, 23:55 UTC

Old Republic International Corp is trading modestly higher in after-market hours, recovering slightly after a series of declines over the previous five sessions.

21 sept. 2026, 23:55 UTC

Carlyle Group Inc is trading modestly lower in after-market hours, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

21 sept. 2026, 23:55 UTC

Mitek Systems Inc is up in after-market trading, reaching a peak despite remaining below its 20-day moving average amid slowing economic growth signals.

21 sept. 2026, 23:55 UTC

Truist Financial Corp is declining in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

21 sept. 2026, 23:55 UTC

Darling Ingredients Inc's stock is trading modestly higher in after-market hours, despite a decline in the Chicago Fed National Activity Index for August.

21 sept. 2026, 23:55 UTC

Solaredge Technologies Inc is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

21 sept. 2026, 23:55 UTC

Booking Holdings Inc. is trading modestly higher in after-market hours following Monday's close, despite remaining significantly below its 20-day moving average.

21 sept. 2026, 23:55 UTC

OraSure Technologies Inc. is trading modestly higher in after-market hours, marking its eighth consecutive session of gains while remaining above its 20-day moving average.

21 sept. 2026, 23:55 UTC

Revolve Group Inc. is trading roughly flat in after-market hours, fluctuating within a range amid economic growth concerns from the Chicago Fed National Activity Index.

21 sept. 2026, 23:52 UTC

News

Boeing Co. has secured two defense contracts worth $41.5 million, while shares have declined slightly in after-market trading, remaining near the lower end of their one-month range.

21 sept. 2026, 23:52 UTC

Yelp Inc. is declining in after-market trading, remaining significantly below its 20-day moving average and continuing a trend of lower daily closes.

21 sept. 2026, 23:51 UTC

Cathay General Bancorp is trading modestly higher in after-market hours, recovering from a slight dip and reaching a peak cumulative return of nearly 1%.

21 sept. 2026, 23:51 UTC

Janus International Group Inc has advanced modestly in after-market trading, continuing a pattern of strength observed throughout the session.

21 sept. 2026, 23:51 UTC

CoStar Group Inc rebounded in after-market trading, showing a cumulative return above its prior close despite remaining below its 20-day moving average.

21 sept. 2026, 23:51 UTC

Cooper Companies Inc is trading modestly higher during after-market hours, despite a significant decline over the past month and trading below its 20-day moving average.

21 sept. 2026, 23:51 UTC

Social Media

Rocket Lab Corp's stock rises in after-market trading following Cantor Fitzgerald's bullish note, reiterating a $122 price target amid successful launches and an upcoming acquisition.

21 sept. 2026, 23:51 UTC

Cabaletta Bio Inc saw notable gains in after-market trading, recovering from a low return shortly after the market closed to a higher return by late session.

21 sept. 2026, 23:51 UTC

Molson Coors Beverage Co sees a modest increase in after-market trading, reaching its highest cumulative return since Monday's close, despite being below its 20-day moving average.

21 sept. 2026, 23:51 UTC

Allstate Corp is seeing notable upward movement in after-market trading, recovering from six consecutive sessions of lower finishes.

21 sept. 2026, 23:51 UTC

CRISPR Therapeutics AG is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

21 sept. 2026, 23:51 UTC

OGE Energy Corp is trading modestly higher in after-market hours, following notable upward movement from its previous close, despite remaining below its 20-day moving average.

21 sept. 2026, 23:51 UTC

United Therapeutics Corp is trading modestly higher in after-market hours, recovering from an initial dip and showing volatility since Monday's close.

Comparaison

Variation de prix

Zentalis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

182.96% hausse

Prévisions sur 12 Mois

Moyen 8.8 USD  182.96%

Haut 11 USD

Bas 5 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

5

Achat

1

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.